ClinicalTrials.gg
RecruitingNCT05114850Updated Apr 3, 2024

Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®

An observational study in Tricuspid Regurgitation, Tricuspid Valve Insufficiency and Tricuspid Insufficiency, sponsored by P+F Products + Features GmbH. Recruiting at 28 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by P+F Products + Features GmbH · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
450
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Tricuspid Valve Insufficiency with a site in Spain — 7 open to participants now, 10 under way, none of them phase 3. Tricuspid Valve Insufficiency · Spain.

Started
2022
with 1 other
Observational
8 of 13
6 open now
Registered
8th of 13
by date
Lead sponsor
2 of 13
P+F Products + Features GmbH

Among the 13 studies in Tricuspid Valve Insufficiency with a site in Spain, this one is one of 2 that started in 2022, is one of 8 observational ones, and was the 8th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

7 of the 13 studies in Tricuspid Valve Insufficiency with a site in Spain are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Tricuspid Valve Insufficiency with a site in Spain, or all of them as a file.
02

Study summary

Retrospective prospective Multicentric clinical follow up of patients with severe tricuspid regurgitation after being treated with the TricValve® Transcatheter Bicaval Valves System.

Read the detailed description

The study shall enrol subjects who were treated with the TricValve® Transcatheter Bicaval Valves System® in the Inferior Vena Cava and Superior vena cava. On compliance with the inclusion / exclusion criteria the subject will be enrolled for the observational study.

The study duration for the individual subject will be up to 5 year follow up. The follow-up should be made through pre-established periodic clinical consultations at discharge, 1 month, 6 months, 1 year follow up to 5 years after the procedure. In the consultations, routine exams such as hemogram, renal function, electrocardiogram and echocardiography in order to ascertain the bioprosthesis functioning and its hemodynamic profile are documented as per clinical routine practise.

03

Conditions studied

  • Tricuspid Regurgitation
  • Tricuspid Valve Insufficiency
  • Tricuspid Insufficiency
  • Heart Failure
  • Heart Diseases
  • Heart Valve Diseases

Keywords

  • Cardiovascular disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study shall enrol subjects who were treated with the TricValve® Transcatheter Bicaval Valves System® in the Inferior Vena Cava and Superior vena cava. On compliance with the inclusion / exclusion criteria the subject will be enrolled for the observational study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Successful treatment with TricValve Transcatheter Bicaval Valves System
  • Patient/patient's authorized legal guardian gives his consent to participate in the study and signed the corresponding inform consent

Exclusion criteria

Exclusion Criteria:

  • no exclusion criterion
05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
450 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Number of patients with readmission for HF

    First unplanned readmission for Heart Failure

    Time frame: up to 12 months

Secondary outcomes

  1. All cause mortality

    Number of patients in terms of all cause mortality

    Time frame: up to 30 days, up to 6 months, up to 5 years

  2. Percentage of participants with major adverse events

    Percentage of participants with major adverse events

    Time frame: up to 12 months

  3. Number of participants with severe adverse events

    Number of participants with severe adverse events

    Time frame: up to 30 days, up to 6 months, up to 5 years

  4. Number of patients with readmission for HF

    First unplanned readmission for Heart Failure

    Time frame: up to 5 years

  5. NYHA functional class

    Change of New York Heart Association (NYHA) functional class from III or IV to a lower one

    Time frame: up to 30 days, up to 6 months, up to 5 years

  6. Change in BNP/NTproBNP and diuretic dosage

    Change in BNP/NTproBNP and diuretic dosage before intervention after intervention

    Time frame: up to 12 months

  7. Change of the right atrium size

    Change of the Right Atrium Size assessed by echocardiography

    Time frame: up to 30 days, up to 6 months, up to 5 years

  8. Change of the free valve movement

    Change of the free valve movement assessed by echocardiography

    Time frame: up to 30 days, up to 6 months, up to 5 years

  9. Valve Device Regurgitation

    Number of patients with valve device regurgitation assessed by echocardiography

    Time frame: up to 30 days, up to 6 months, up to 5 years

  10. Number of alive patients

    Number of alive patients free from reintervention related to TricValve System

    Time frame: up to 30 days, up to 6 months, up to 5 years

07

Study locations

12 of 28 sites recruiting
  • Universitätsklinikum St. Pölten
    St. Poelten, Niederoesterreich 3100, Austria
    Not yet recruiting
    • Julia Mascherbauer, Dr · Contact
  • Medizinische Universität Wien, Department of Cardiac Surgery
    Vienna, 1090, Austria
    Not yet recruiting
    • Martin Andreas, Dr · Contact
  • Medizinische Universität Wien, Universitätsklinik für Innere Medizin II
    Vienna, 1090, Austria
    Not yet recruiting
    • Christian Hengstenberg, UnivProf Dr · Contact
  • Department of Cardiology, Algemeen Stedelijk Ziekenhuis (ASZ)
    Aalst, 9300, Belgium
    Not yet recruiting
    • Liesbeth Rosseel, Dr · Contact
  • RkK gGmbH im Artemed Klinikverbund Freiburg
    Freiburg, 79104, Germany
    Not yet recruiting
    • Tilmann Schwab, MD · Contact
  • Universitätsklinikum Freiburg
    Freiburg, 79189, Germany
    Not yet recruiting
    • Martin Czerney, MD · Contact
  • Klinikum Friedrichshafen
    Friedrichshafen, 88048, Germany
    Not yet recruiting
    • Jochen Wöhrle, MD · Contact
  • SLK-Kliniken Heilbronn GmbH
    Heilbronn, 74078, Germany
    Not yet recruiting
    • Marcus Hennersdorf, MD · Contact
  • Universitätsklinikum Regensburg
    Regensburg, 93053, Germany
    Not yet recruiting
    • Bernhard Unsöld, MD · Contact
  • Robert-Bosch-Krankenhaus
    Stuttgart, 70376, Germany
    Not yet recruiting
    • Phillip Nikolai, MD · Contact
  • Rems-Murr-Kliniken
    Winnenden, 71364, Germany
    Not yet recruiting
    • A. Jeron, MD · Contact
  • Cardiothoracic and Vascular Surgery Clinic of Hospital of LSMUH Kaunas Klinikos
    Kaunas, Lithuania
    Not yet recruiting
    • Rimantas Benetis, Dr · Contact
  • Hospital de Galdakao-Usansolo
    Galdakao, Bizkaia 48960, Spain
    Not yet recruiting
    • Jose R Rumoroso, Dr · Contact
  • Hospital Virgen de la Victoria
    Málaga, Malaga 29010, Spain
    Not yet recruiting
    • Jose M Hernandez, Dr · Contact
  • Parc de Salut Mar
    Barcelona, 08003, Spain
    Recruiting
    • Beatriz Vaquerizo Montilla, Dr · Contact
  • Hospital Clinic Barcelona
    Barcelona, 08036, Spain
    Recruiting
    • Xavier Freixa Rofastes, Dr · Contact
  • Hospital Universitari de Bellvitge
    Barcelona, 08907, Spain
    Not yet recruiting
    • Joan Antoni Gomez, Dr · Contact
  • Hospital Universitari Germans Trias i Pujol
    Barcelona, Spain
    Recruiting
    • Xavier Suarez, Dr · Contact
  • Hospital Universitario Reina Sofia de Córdoba
    Córdoba, Spain
    Recruiting
    • Manuel Pan Alvarez, Dr · Contact
  • Hospital Universitario Lucus Augusti
    Lugo, 27003, Spain
    Recruiting
    • Raymundo Ocaranza Sánchez, Dr · Contact
  • Hospital Universitario Puerta de Hierro de Majadahonda
    Madrid, 28222, Spain
    Not yet recruiting
    • Maria del Trigo Espinosa, Dr · Contact
  • Hospital Clínico San Carlos
    Madrid, Spain
    Recruiting
    • Luis Nombela Franco, Dr · Contact
  • Hospital Universitario La Paz
    Madrid, Spain
    Recruiting
    • Raul Moreno, Dr · Contact
  • Hospital Universitario Ramón y Cajal
    Madrid, Spain
    Recruiting
    • Ángel Sánchez Recalde, Dr · Contact
  • Hospital Universitario Central Asturias
    Oviedo, Spain
    Recruiting
    • César Morís, MD · Contact
  • Hospital Clínico Universitario de Salamanca
    Salamanca, Spain
    Recruiting
    • Ignacio Cruz, Dr · Contact
  • Hospital Clínico Universitario de Valladolid
    Valladolid, Spain
    Recruiting
    • Ignacio J Amat Santos, Dr · Contact
  • Hospital Universitario Alvaro Cunqueiro
    Vigo, Spain
    Recruiting
    • Andrés Iniguez Romo, Dr · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Dec 2025, 44 months after the start.

Of 47 observational studies under Tricuspid Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 106. This study's planned 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2021
First posted
Nov 10, 2021
StartActual
Apr 20, 2022
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2028
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05114850
Lead sponsor
P+F Products + Features GmbH
Responsible party
Sponsor
First posted
Nov 10, 2021
Start date
Apr 20, 2022
Primary completion
Dec 2025 (estimated)
Completion
Dec 2028 (estimated)
Last update
Apr 3, 2024

Study contacts

Sandra Scheidl, MSc
Contact
sscheidl@pfcardiovascular.com
+436601148208
Benjamin Reutterer, Dr
Contact
breutterer@pfcardiovascular.com
+4369917237200
Ignacio J Amat Santos, Dr
principal investigator · Hospital Clínico Universitario de Valladolid

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion